Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Name /bks_53161_deglins_md_disk/fusidicacid 02/25/2014 10:01AM 1 Plate # 0-Composite pg 1 # 1 Use Cautiously in: OB: Safe use during pregnancy has not been established, po- Canada-Approved Medicine: This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the U.S. fusidic acid (fyoo-sid-ik as-id) tential benefits should be weighed against the possible hazards to the fetus (crosses the placenta); Lactation: Safe use during breast feeding has not been established (enters breast milk). Adverse Reactions/Side Effects Derm: mild local irritation. Interactions Drug-Drug: None noted for topical use. Fucidin, Fucithalmic Classification Therapeutic: anti-infectives Route/Dosage Topical (Adults and Children): Apply to affected area 3– 4 times daily. Ophth (Adults and Children): One drop into conjunctival sac of both eyes every 12 hr for 7 days. Indications Topical — Local treatment of primary and secondary bacterial skin infections including impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds/burns. Ophthalmic— Treatment of superficial eye infections. Action Inhibits bacterial protein synthesis. Therapeutic Effects: Resolution of localized bacterial infections. Not active against Gram-negative organisms; active against Staphylococci , Streptococci and Corynebacterium. NURSING IMPLICATIONS Assessment ● Inspect involved areas of skin and mucous membranes before and frequently dur- ing therapy. Increased skin irritation may indicate need to discontinue medication. Potential Nursing Diagnoses Pharmacokinetics Absorption: Unknown. Distribution: Systemically absorbed drug crosses the placenta and enters breast Risk for infection (Indications) Acute pain (Indications) milk. ● Do not confuse topical product with ophthalmic product. ● Topical: Consult health care professional for proper cleansing technique before Metabolism and Excretion: Absorbed drug is extensively metabolized. Half-life: 5– 6 hr. TIME/ACTION PROFILE ROUTE Top ophth ONSET unknown unknown PEAK unknown unknown DURATION 6–8 hr 12 hr Contraindications/Precautions Contraindicated in: Hypersensitivity to fusidic acid or other components of the formulation (topical ointment contains lanolin). ⫽ Canadian drug name. ⫽ Genetic Implication. Implementation applying medication. Apply small amount to cover affected area completely. Avoid the use of occlusive wrappings or dressings unless directed by health care professional. ● Ophth: Administer 1 drop into conjunctival sac of both eyes every 12 hours for 7 days. See Appendix D for instructions. Patient/Family Teaching ● Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes. CAPITALS indicate life-threatening, underlines indicate most frequent. Strikethrough ⫽ Discontinued. PDF Page #1 Name /bks_53161_deglins_md_disk/fusidicacid 02/25/2014 10:01AM Plate # 0-Composite pg 2 # 2 2 ● Advise patient to report increased skin irritation or lack of response to therapy to PDF Page #2 health care professional. Evaluation/Desired Outcomes ● Resolution of skin or eye infection. Why was this drug prescribed for your patient? 䉷 2015 F.A. Davis Company